Company / SG&A Expense
Rein Therapeutics, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.9M
FY2025
5-year range
$9.3M / $13.9M
FY2021-FY2025
Trend
+22.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 4 consecutive years, from $9M in FY2021 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +2.4%.
Increased from $10M to $14M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +13.0%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Rein Therapeutics, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 22.1% year-over-year.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.9M | +22.1% |
| FY2024 | $11.4M | +17.3% |
| FY2023 | $9.7M | +0.9% |
| FY2022 | $9.6M | +2.9% |
| FY2021 | $9.3M | -24.1% |
| FY2020 | $12.3M | -8.6% |
| FY2019 | $13.5M | +53.4% |
| FY2018 | $8.8M | +73.3% |
| FY2017 | $5.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026